Hosted on MSN1mon
Ionis stock rises on FDA, EMA nod for SMA drug dose increase
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are now reviewing the ... The announcement marks a potential advancement for SMA care and has been positively ...
Solana price bottom below $100? Death cross hints at 30% drop
Solana price faces another 30% decline if the altcoin is unable to defend $110 level during further market corrections.
pharmaphorum1d
Novartis closes on EU approval for SMA gene therapy Zolgensma
Now, the CHMP has backed conditional approval of Zolgensma for babies and young children with SMA, which could lead to full EMA approval within the next couple of months. Novartis says it will ...
Business Wire1mon
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
Evrysdi is designed to treat SMA by increasing and sustaining the production ... Evrysdi was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation ...